rolvedon
Generic: eflapegrastim-xnst
rolvedon: sourced relationships with 2 companies · 1 FDA decision.
rolvedon evidence translation
What we can confirm
1 FDA record
What it means
More than one company relationship is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.
What to watch
Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected
Prepared research question
What is verified about rolvedon, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugschemotherapy-induced neutropenia
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| Assertio Holdings, Inc. (ASRT) Decrease the incidence of infection, as manifested by febril… | Approved |
| SPECTRUM PHARMACEUTICALS INC (SPPI) chemotherapy-induced neutropenia | Approved |
FDA Decisions1 records
Frequently asked questions
Which companies have sourced relationships with rolvedon?
rolvedon has dated SEC/FDA relationship records for Assertio Holdings, Inc., SPECTRUM PHARMACEUTICALS INC.
What is rolvedon's latest FDA decision?
The most recent tracked FDA decision for rolvedon is Approval, dated September 9, 2022.